World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
64
Citations
15714
World Ranking
2923
National Ranking
109

Overview

Tuna Mutis is affiliated with the Vrije Universiteit Amsterdam in the Netherlands. Their research primarily spans the field of Medicine with a focus on Oncology, Immunology, Hematology, Molecular Biology, and Radiology, Nuclear Medicine and Imaging. The subfields of study include:

  • Oncology
  • Immunology
  • Hematology
  • Molecular Biology
  • Radiology, Nuclear Medicine and Imaging

The principal topics of their work concentrate on areas related to immune and cancer research, specifically:

  • CAR-T cell therapy research
  • Multiple Myeloma Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • T-cell and B-cell Immunology

Tuna Mutis has contributed to a number of scientific publications across several well-established venues, including:

  • Blood
  • HemaSphere
  • Cancers
  • Blood Advances
  • Clinical Cancer Research

Their recent papers include:

  • Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma, 2021, Blood Advances
  • Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab, 2020, Leukemia
  • CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide, 2020, Haematologica
  • Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence, 2021, Science Translational Medicine
  • Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment, 2021, Blood Cancer Journal

Frequent collaborators in their work include:

  • Sonja Zweegman
  • Niels W.C.J. van de Donk
  • Christie P.M. Verkleij
  • Wassilis S.C. Bruins
  • Kristine A. Frerichs

Best Publications

  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

    Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker

  • Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

    Jakub Krejcik;Jakub Krejcik;Tineke Casneuf;Inger S. Nijhof;Bie Verbist

  • Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.

    W. A. Erik Marijt;Mirjam H. M. Heemskerk;Freke M. Kloosterboer;Els Goulmy

  • Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

    M. B. Overdijk;S. Verploegen;M. Bogels;M. van Egmond

  • Feasibility of Immunotherapy of Relapsed Leukemia With Ex Vivo–Generated Cytotoxic T Lymphocytes Specific for Hematopoietic System-Restricted Minor Histocompatibility Antigens

    Tuna Mutis;Rob Verdijk;Ellen Schrama;Bennie Esendam

  • Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)) Induces Stable Maturation of Functionally Active Human Dendritic Cells

    Rob M. Verdijk;Tuna Mutis;Ben Esendam;Janine Kamp

  • Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization

    Jorg Van Loosdregt;Yvonne Vercoulen;Teun Guichelaar;Yoony Y J Gent

  • CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

    Inger S. Nijhof;Inger S. Nijhof;Tineke Casneuf;Jeroen van Velzen;Berris van Kessel

  • Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.

    T. Mutis;G. Gillespie;E. Schrama;J.H.F. Falkenburg

  • Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

    Niels W. C. J. van de Donk;Maarten L. Janmaat;Tuna Mutis;Jeroen J. Lammerts van Bueren

  • In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens

    Anne M. Dickinson;Xiao Nong Wang;Lisbet Sviland;Florry A. Vyth-Dreese

  • Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin

    Yvonne van de Wal;Yvonne M. C. Kooy;Peter A. van Veelen;Salvador A. Peña

  • Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

    Michael. S. van der Veer;Michel de Weers;Berris van Kessel;Joost M. Bakker

  • A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization

    Esther Drent;Maria Themeli;Renée Poels;Regina de Jong-Korlaar

  • Pregnancy induces minor histocompatibility antigen–specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy

    Rob M Verdijk;Antoinette Kloosterman;Jos Pool;Maarten van de Keur

  • Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

    Esther Drent;Richard W. J. Groen;Willy A. Noort Noort;Maria Themeli

  • Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

    Evelien Kneppers;Bronno van der Holt;Marie-Jose Kersten;Sonja Zweegman

  • Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab

    Jakub Krejcik;Jakub Krejcik;Kris A. Frerichs;Inger S. Nijhof;Berris van Kessel

  • Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation

    Eric Spierings;Corine J. Vermeulen;Mario H. Vogt;Lucie E.E. Doerner

  • Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib

    Inger S. Nijhof;Inger S. Nijhof;Richard W.J. Groen;Richard W.J. Groen;Willy A. Noort;Willy A. Noort;Berris van Kessel;Berris van Kessel

  • The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein.

    R. A. Pierce;E. D. Field;T. Mutis;T. N. Golovina

Frequent Co-Authors

Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Henk M. Lokhorst
Henk M. Lokhorst VU University Medical Center
Els Goulmy
Els Goulmy Leiden University Medical Center
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Gert Storm
Gert Storm Utrecht University
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
Anneke Brand
Anneke Brand Leiden University Medical Center
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center
Margaret A. Lindorfer
Margaret A. Lindorfer University of Virginia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare careers can open various opportunities. Many students pursue advanced nursing paths, such as becoming a Doctor of Nursing Practice (DNP). Understanding the doctor of nursing practice salary by state can help prospective students gauge the financial benefits alongside rigorous training.

If you're a Family Nurse Practitioner looking to specialize, obtaining an acute care NP certification is a valuable step. This certification allows nurses to focus on patients with severe, complex conditions, often aligned with immunological disorders.

Online education offers flexibility for those pursuing nursing careers related to immunology. Accelerated programs, such as the accelerated RN to NP programs, enable registered nurses to advance quickly in their careers, transitioning to nurse practitioners within a shorter timeframe.

For individuals new to the field, online RN programs for non nurses provide accessible entry points into nursing. These programs build foundational skills necessary to later specialize in areas like immunology or advanced practice nursing.

Best Scientists Citing Tuna Mutis

Trending Scientists